...
首页> 外文期刊>Strahlentherapie und Onkologie >Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : An Open-Label Comparative Cohort Trial.
【24h】

Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : An Open-Label Comparative Cohort Trial.

机译:在原发性或复发性局部晚期胰腺癌中局部热疗联合放化疗:一项开放标签比较队列试验。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the therapeutic effect of delivering regional hyperthermia (HT) plus chemoradiotherapy (CRT) in patients suffering from locally advanced unresectable pancreatic cancer (LAPC). METHODS: Between January 2000 and December 2008, 68 patients affected by primary (56/68) or recurrent (12/68) LAPC were treated either with CRT alone or CRT plus HT. Radiotherapy (RT) consisted of 3D conformal irradiation of tumor and regional lymph nodes (dose ranged from 30 Gy/10 fractions to 66 Gy/33 fractions). Chemotherapy (CT) consisted of gemcitabine (GEM) alone or in association with either oxaliplatin, cisplatin, or 5-FU. HT was delivered twice a week, concomitant with RT. RESULTS: In the current study, 60 of the original 68 patients were included. Median overall survival (OS) was 15 months in the HT group versus 11 months in the control group (log-rank test: p = 0.025). HT did not increase CRT toxicity. CONCLUSION: HT can be added safely to CRT in LAPC, thus, resulting in slightly prolonged survival in certain cases.
机译:目的:评估局部热疗(HT)和放化疗(CRT)对局部晚期不可切除的胰腺癌(LAPC)患者的治疗效果。方法:自2000年1月至2008年12月,对68例原发性(56/68)或复发性(12/68)LAPC患者进行了单独CRT或CRT加HT治疗。放射疗法(RT)包括肿瘤和局部淋巴结的3D保形照射(剂量范围从30 Gy / 10馏分到66 Gy / 33馏分)。化学疗法(CT)由单独的吉西他滨(GEM)或与奥沙利铂,顺铂或5-FU联合使用组成。 HT每周两次,与RT并存。结果:在本研究中,最初的68位患者中有60位被纳入研究。 HT组中位总生存期(OS)为15个月,而对照组为11个月(对数秩检验:p = 0.025)。 HT没有增加CRT毒性。结论:HT可以安全地添加到LAPC的CRT中,因此,在某些情况下可以稍微延长生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号